- Home
- VTVT vs CRIS Comparison
VTVT vs CRIS Comparison
Compare VTVT & CRIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTVT
- CRIS
- Stock Information
- Founded
- VTVT 2015
- CRIS 2000
- Country
- VTVT United States
- CRIS United States
- Employees
- VTVT N/A
- CRIS N/A
- Industry
- VTVT Biotechnology: Pharmaceutical Preparations
- CRIS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VTVT Health Care
- CRIS Health Care
- Exchange
- VTVT Nasdaq
- CRIS Nasdaq
- Market Cap
- VTVT 38.8M
- CRIS 32.8M
- IPO Year
- VTVT 2015
- CRIS 2000
- Fundamental
- Price
- VTVT $14.05
- CRIS $3.29
- Analyst Decision
- VTVT Strong Buy
- CRIS Strong Buy
- Analyst Count
- VTVT 1
- CRIS 3
- Target Price
- VTVT $35.00
- CRIS $23.00
- AVG Volume (30 Days)
- VTVT 8.5K
- CRIS 243.3K
- Earning Date
- VTVT 03-12-2025
- CRIS 02-06-2025
- Dividend Yield
- VTVT N/A
- CRIS N/A
- EPS Growth
- VTVT N/A
- CRIS N/A
- EPS
- VTVT N/A
- CRIS N/A
- Revenue
- VTVT $1,000,000.00
- CRIS $10,259,000.00
- Revenue This Year
- VTVT N/A
- CRIS N/A
- Revenue Next Year
- VTVT N/A
- CRIS N/A
- P/E Ratio
- VTVT N/A
- CRIS N/A
- Revenue Growth
- VTVT 11011.11
- CRIS 0.44
- 52 Week Low
- VTVT $7.38
- CRIS $2.86
- 52 Week High
- VTVT $30.99
- CRIS $17.49
- Technical
- Relative Strength Index (RSI)
- VTVT 46.82
- CRIS 44.97
- Support Level
- VTVT $13.90
- CRIS $3.10
- Resistance Level
- VTVT $14.35
- CRIS $3.60
- Average True Range (ATR)
- VTVT 0.58
- CRIS 0.37
- MACD
- VTVT 0.03
- CRIS 0.00
- Stochastic Oscillator
- VTVT 42.61
- CRIS 26.22
About VTVT vTv Therapeutics Inc.
vTv Therapeutics Inc is a clinical stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases to minimize their long-term complications and improve the lives of patients. Itsproduct pipeline include TTP399, TTP273, HPP737, HPP593, Azeliragon, HPP971, HPP3033, and TTP-RA.
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.